Aerie Pharmaceuticals reported $385.34M in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Aerie Pharmaceuticals AERI:US $ 385.34M 10.21M
Alimera Sciences ALIM:US $ 47.57M 2.36M
Amarin AMRN:US $ 973.24M 0.47M
Bluebird Bio BLUE:US $ 573.59M 82.52M
Cara Therapeutics CARA:US $ 226.57M 2.71M
Coherus Biosciences CHRS:US $ 546M 47.38M
Endo International Ordinary Shares ENDP:US $ 6362.26M 2084.95M
Horizon Pharma HZNP:US $ 8853.47M 113.14M
Insmed INSM:US $ 1.05B 99.96M
JAZZ PHA JAZZ:US $ 11200.13M 568.78M
Mirati Therapeutics MRTX:US $ 1279.79M 141.51M
Novartis NOVN:VX SF 122910M 2308M
Ophthotech OPHT:US $ 319.76M 32.95M
Pacira Pharmaceuticals PCRX:US $ 1733.99M 157.49M
Regeneron Pharmaceuticals REGN:US $ 27205.8M 857.1M
Revance Therapeutics RVNC:US $ 561.88M 77.66M
Supernus Pharmaceuticals SUPN:US $ 1694.97M 55.46M
Teva Pharmaceutical Industries TEVA:US $ 45932M 1127M
Valeant Pharmaceuticals VRX:CN $ 36261.71M 7171.71M
Zoetis ZTS:US $ 13770M 90M